Possible contribution of prostaglandin E2 to the antiproliferative effect of phosphodiesterase 4 inhibitors in human mononuclear cells

Biochemical Pharmacology

Volumn 58, Issue 9, 1999, Pages 1487-1495

  Banner, Kathy H ^a   Hoult, J Robin S ^a   Taylor, Magali N ^a   Landells, Linda J ^a   Page, Clive P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Isoenzyme selective PDE inhibitors; Peripheral blood mononuclear cells; Prostaglandin E2

Indexed keywords

4 [2 [3 (CYCLOPENTYLOXY) 4 METHOXYPHENYL] 2 PHENYLETHYL]PYRIDINE; BUCLADESINE; CYCLIC AMP; CYCLIC AMP PHOSPHODIESTERASE; FORSKOLIN; INDOMETACIN; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE INHIBITOR; ROLIPRAM; THEOPHYLLINE; ZARDAVERINE;

ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; MONONUCLEAR CELL; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CELL DIVISION; CYCLIC AMP; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG INTERACTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; PHOSPHODIESTERASE INHIBITORS; THEOPHYLLINE;

EID: 0032870263     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00223-3     Document Type: Article

References (44)

1. Azzawi M., Johnston P.W., Majamdar S., Kay A.B., Jeffery P.K. T lymphocytes and activated eosinophils in airway mucosa in fatal asthma and cystic fibrosis. Am Rev Respir Dis. 145:1992;1477-1482.
2. Coffey R.A. Intracellular events during lymphocyte activation. Bray M.A., Morley J. Handbook of Experimental Pharmacology. Vol. 85:1988;83-138 Springer, New York.
3. Goodwin J., Bankhurst A., Messner R. Suppression of human T cell mitogenesis by prostaglandin. J Exp Med. 14:1977;1719-1733.
4. 3 and agents that increase intracellular adenosine 3′,5′-monophosphate synergistically inhibit the mitogenic stimulation of human lymphocytes. J Clin Endocrinol Metab. 70:1990;1687-1692.
5. Giembycz M.A., Kelly J.J. Current status of cyclic nucleotide phosphodiesterase isoenzymes. Costello J.F., Piper P.J. Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease. 1994;27-80 Parthenon Publishing Group, Carnforth, U.K.
6. Beavo J.A. Cyclic nucleotide phosphodiesterases Functional implications of multiple isoforms . Physiol Rev. 75:1995;725-748.
7. + T-lymphocytes Role in regulating proliferation and the biosynthesis of interleukin-2 . Br J Pharmacol. 118:1996;1945-1958.
8. Robicsek S.A., Blanchard D.K., Djeu J.Y., Krzanowski J.J., Szentivanyi A., Polson J.B. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol. 42:1991;869-877.
9. Schudt C., Winder S., Muller B., Ukena D. Zardaverine as a selective inhibitor of phosphodiesterase isozymes. Biochem Pharmacol. 42:1991;153-162.
10. Tenor H., Hatzelmann A., Kupferschmidt R., Stanciu L., Djukanovic R.M., Schudt C., Wendel A., Church M.K., Shute J.K. Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin Exp Allergy. 25:1995;625-633.
11. + T lymphocytes. Clin Exp Allergy. 25:1995;616-624.
12. Thompson W.J., Ross C.P., Pledger W.J., Strada S.J., Banner R.L., Hersh E.M. Cyclic adenosine 3′,5′-monophosphate phosphodiesterase Distinct forms in human lymphocytes and monocytes . J Biol Chem. 251:1976;4922-4929.
13. Schudt C., Tenor H., Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J. 8:1995;1179-1183.
14. Ichimura M., Kase H. A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. Biochem Biophys Res Commun. 193:1993;985-990.
15. Li L., Yee C., Beavo J.A. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 283:1999;848-851.
16. Bruserud O. The effect of theophylline on T-lymphocyte activation in vitro. Clin Immunol Immunopathol. 32:1984;111-118.
17. Banner K.H., Roberts N.M., Page C.P. Differential effect of phosphodiesterase 4 inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br J Pharmacol. 116:1995;3169-3174.
18. 2 and phosphodiesterase inhibitors on Con A blastogenic responses and NK cytotoxic activity of mouse spleen cells. J Leukoc Biol. 47:1990;371-377.
19. 2 regulation of cytokine production in atopic dermatitis. J Immunol. 151:1993;3345-3352.
20. Kenakin T.P. Pharmacologic Analysis of Drug-Receptor Interaction. 1987;Raven Press, New York.
21. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors New opportunities for the treatment of asthma . Thorax. 46:1991;512-523.
22. Nicholson C.D., Challiss R.A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase enzymes. Trends Pharmacol Sci. 12:1991;19-27.
23. Pazdur J., Krzystyniak K., Kopec M. Effects of dipyridamole on human blood lymphocytes. Biochem Pharmacol. 29:1980;2515-2517.
24. Brune K., Rainsford K.D., Wagner K., Peskar B.A. Inhibition by anti-inflammatory drugs of prostaglandin production in cultured macrophages. Naunyn-Schmiedebergs Arch Pharmacol. 315:1981;269-276.
25. 2-induced T-lymphocyte proliferative suppression in sepsis. Infect Immun. 63:1995;3101-3105.
26. Whitaker M. Regulation of the cell division cycle by inositol trisphosphate and the calcium signalling pathway. Means A.R. Advances in Second Messenger and Phosphoprotein Research. Vol. 30:1995;299-310 Raven Press, New York.
27. Cardenas M.E., Heitman J. Role of calcium in T-lymphocyte activation. Means A.R. Advances in Second Messenger and Phosphoprotein Research. Vol. 30:1995;281-298 Raven Press, New York.
28. Kantor H.S., Hampton M. Indomethacin in submicromolar concentrations inhibits cAMP-dependent protein kinase. Nature. 276:1978;841-842.
29. Ciosek C.P., Ortel R.W., Thanassi N.M., Newcombe D.S. Inhibition of phosphodiesterase by nonsteroidal anti-inflammatory drugs. Nature. 251:1974;148-150.
30. 2 activity in rat and human lymphocytes. Biochem Biophys Res Commun. 125:1984;719-727.
31. 2 of rabbit polymorphonuclear leukocytes. Proc Natl Acad Sci USA. 75:1978;2955-2958.
32. 2 Selective inhibition of group II enzymes by indomethacin but not other NSAIDs . Agents Actions. 41:1994;111-113.
33. Pang L., Hoult J.R.S. Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin Enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase . Eur J Pharmacol. 317:1996;151-155.
34. 4 in a novel human whole blood assay. Br J Pharmacol. 126:1999;979-988.
35. Sinha B., Semmler J., Eisenhut T., Eigler A., Endres S. Enhanced tumor necrosis factor suppression and cyclic adenosine monophosphate accumulation by combination of phosphodiesterase inhibitors and prostanoids. Eur J Immunol. 25:1995;147-153.
36. 2-adrenoreceptor desensitization. J Biol Chem. 273:1998;20575-20588.
37. Inoue H., Nanayama T., Hara S., Yokoyama C., Tanabe T. The cyclic AMP response element plays an essential role in the expression of the human prostaglandin-endoperoxide synthase 2 gene in differentiated U937 monocytic cells. FEBS Lett. 350:1994;51-54.
38. 2 on the induction of nitric oxide- and prostanoid-forming pathways in cultured mesangial cells. Biochem J. 313:1996;617-623.
39. 2 by bovine cultured airway smooth muscle cells Regulation by cAMP . J Appl Physiol. 78:1995;623-628.
40. 4 synthesis and chemotaxis of human eosinophils from normal and atopic subjects. Br J Pharmacol. 118:1996;1727-1735.
41. 4 in activated neutrophils by nimesulide due to an elevation of intracellular cyclic adenosine monophosphate. Arzneimittelforschung. 45:1995;1110-1114.
42. Horrobin D.F., Manku M.S., Franks D.J., Hamet P. Methylxanthine phosphodiesterase inhibitors behave as prostaglandin antagonists in a perfused rat mesenteric artery preparation. Prostaglandins. 13:1977;33-40.
43. 2-induced suppression. J Immunol. 142:1989;4346-4350.
44. 2 and immunomodulation with indomethacin. J Immunol. 151:1993;2142-2149.